Randomization and alternatives;Randomisering og alternativer

Ugeskrift for Laeger

Volumn 161, Issue 18, 1999, Pages 2657-2660

  Olsen, Jørn ^a   Olesen, Charlotte ^b  

^a Ctr Epidemiologisk Grundforskning   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FOLLOW UP; HUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW;

CASE-CONTROL STUDIES; FOLLOW-UP STUDIES; HUMANS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS;

EID: 0033519119     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. DBCG. København: DBCG's sekretariat 1997.
2. Strom BL, ed. Pharmacoepidemiology. 2nd ed. Paul Wiley and Sons, 1989.
3. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. J Am Med Assoc 1995; 273: 408-12.
4. Campbell JP, Maxey VA, Watson WA. Hawthorne effect: implications for prehospital research. Ann Emerg Med 1995; 26: 590-4.
5. Miettinen OS. Theoretical epidemiology. New York: John Wiley & Sons, 1985: 30.
6. Edwardes MD, Baltzan M. Confounding by indication, histamine-2 receptor antagonists, and gastric cancer. Epidemiology 1997; 8: 335.
7. Blais L, Ernst P, Suissa S. Confounding by indication and channeling over time: the risks of beta 2-agonists. Am J Epidemiol 1996; 144: 1161-9.
8. Walker AM. Confounding by indication. Epidemiology 1996; 7: 335-6.
9. Shapiro S. Confounding by indication. Epidemiology 1997; 8: 110-1.
10. Miettinen O, Cook F. Confounding; essence and detection. Am J Epidemiol 1981; 114: 593-607.
11. Strom BL, Miettinen O, Melmon KL. Postmarketing studies of drug efficacy: when must they be randomized. Clin Pharmacol Ther 1983; 34: 1-7.
12. Rothman KJ. Confounding by indication. Epidemiology 1996; 7: 335-6.
13. Manjula D. You cannot exclude the explanation you have not considered. Lancet 1993; 342: 345-7.
14. Miettinen O. Confounding and effect-modification. Am J Epidemiol 1995; 141: 1113-6.
15. Weinberg CR. Toward a clearer definition of confounding. Am J Epidemiol 1993; 137: 1-8.
16. Olsen J, Andersen AMN. Design af case-kontrolundersogelser. En opdatering. Bibl Læger 1996; 188: 366-86.
17. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS. Selection of controls in case-control studies. III. Design options. Am J Epidemiol 1992; 135: 1042-50.
18. Wacholder S, McLaughlin JK, Silverman DT, Mandel JS. Selection of controls in case-control studies. I. Principles. Am J Epidemiol 1992; 135: 1019-28.
19. Black N. Why we need observational studies to evaluate the effectiveness of health care. Br Med J 1996; 312: 1215-8.
20. Torgerson DJ, Sibbald B. What is a patient preference trial. Br Med J 1998; 316: 360.
21. Zelen M. Play the winner rule and the controlled clinical trial. J Am Stat Assoc 1969; 64: 131-46.
22. Simon R. Adaptive treatment assignment methods and clinical trials. Biometrics 1977; 33: 743-9.
23. Ware JH. Investigation therapies of potential great benefit: ECMD. Stat Science 1989; 4: 298-340.
24. Zelen M. A new design for randomized clinical trials. N Engl J Med 1979; 300: 1242-5.
25. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colerectal cancer with feacal-occult-blood test. Lancet 1996; 348: 1467-71.